Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis
{{output}}
Background: Platform therapies, such as dimethylfumarate, teriflunomide, and interferons beta, are insufficient to control relapsing-remitting multiple sclerosis in many patients. Having biomarkers available to stratify patients ... ...
